Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28018198 | 0.77 | CYP2A6 (0.47) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL18290416 | 0.74 | KDM4E (0.48) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL22766223 | 0.74 | KDM4E (0.44) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL24894303 | 0.74 | FLT3 (0.48) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL18525704 | 0.74 | ALDH1A1 (0.45) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL21445782 | 0.72 | FLT3 (0.52) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL11757331 | 0.70 | FLT3 (0.55) | FLT3TYRDAOAKR1B1HPGD | |
| SCHEMBL96257 | 0.69 | CYP2A6 (0.64) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL31495889 | 0.69 | CCR2 (0.42) | CYP2A6FLT3TYRDAOAKR1B1 | |
| SCHEMBL18290408 | 0.69 | KDM4E (0.42) | CYP2A6FLT3TYRDAOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786079-B2 | Substituted nonadepsipeptides | AICURIS GMBH & CO. KG. (DE) | 2010-08-31 | — | — | US | disclosed |
| EP-1809653-B1 | SUBSTITUTED NONADEPSIPEPTIDES | AICURIS GMBH & CO KG (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20080058251-A1 | Substituted nonadepsipeptides | BAYER HEALTHCARE AG (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1809653-A1 | SUBSTITUTED NONADEPSIPEPTIDES | AiCuris GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006042654-A1 | SUBSTITUTED NONADEPSIPEPTIDES | AICURIS GMBH & CO. KG (DE) | 2006-04-27 | — | — | WO | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058251-A1 | Substituted nonadepsipeptides | VIP, DNPEP, LNPEP | CYP2A6 3442/4885FLT3 786/4885TYR 621/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | CYP2A6 833/4885FLT3 4203/4885TYR 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.